rational
ex
vivo
bronchial
epitheli
cell
peopl
asthma
suscept
rhinoviru
infect
caus
defici
induct
antivir
protein
ifnb
exogen
ifnb
restor
antivir
activ
object
compar
efficaci
safeti
inhal
ifnb
placebo
administ
peopl
asthma
onset
cold
symptom
prevent
attenu
asthma
symptom
caus
respiratori
virus
method
total
peopl
asthma
inhal
corticosteroid
british
thorac
societi
step
histori
virusassoci
exacerb
random
treatment
inhal
ifnb
n
placebo
n
within
hour
develop
cold
symptom
assess
clinic
relev
sampl
collect
assess
viru
infect
antivir
respons
measur
main
result
total
random
patient
develop
defin
cold
modifi
intentiontotreat
popul
asthma
symptom
get
clinic
significantli
wors
mean
chang
sixitem
asthma
control
questionnair
ifnb
treatment
signific
effect
primari
endpoint
although
enhanc
morn
peak
expiratori
flow
recoveri
p
reduc
need
addit
treatment
boost
innat
immun
assess
blood
sputum
biomark
exploratori
analysi
subset
difficulttotreat
step
peopl
asthma
n
ifnb
n
placebo
asthma
control
increas
significantli
placebo
prevent
ifnb
p
conclus
although
trial
meet
primari
endpoint
suggest
inhal
ifnb
potenti
treatment
virusinduc
deterior
asthma
difficulttotreat
peopl
asthma
support
need
adequ
power
trial
popul
clinic
trial
regist
wwwclinicaltrialsgov
nct
exacerb
asthma
major
caus
respiratori
virus
larg
unmet
medic
need
especi
sever
diseas
peopl
asthma
like
develop
lower
respiratori
tract
symptom
upper
respiratori
tract
infect
urti
even
though
frequenc
sever
cold
peopl
asthma
higher
normal
use
cultur
bronchial
epitheli
cell
obtain
bronchoscop
brush
corticosteroidtr
peopl
asthma
previous
demonstr
infect
rhinovirus
rv
asthmat
bronchial
epithelium
fail
mount
effect
innat
immun
respons
involv
ifnb
ifnl
suboptim
activ
antivir
pathway
result
greater
viral
replic
shed
cytolysi
epitheli
cell
mediat
releas
similar
defect
exist
asthmat
airway
macrophag
airway
cell
children
asthma
importantli
epitheli
antivir
activ
could
correct
ex
vivo
low
concentr
exogen
ifnb
studi
unabl
replic
differ
peopl
asthma
healthi
individu
conduct
mild
corticosteroidna
peopl
asthma
wellcontrol
asthma
evalu
clinic
relev
ifnb
defici
asthma
explor
potenti
ifnb
treatment
virusinduc
asthma
exacerb
seri
clinic
studi
conduct
inhal
ifnb
synairgen
research
ltd
southampton
uk
see
onlin
supplement
doseescal
studi
volunt
asthma
show
nebul
ifnb
miu
given
daili
day
well
toler
enhanc
innat
immun
respons
airway
assess
sever
biomark
ifnbrel
antivir
activ
neopterin
ifnginduc
protein
myxoma
resist
protein
oligoadenyl
synthetas
measur
induc
sputum
see
figur
onlin
supplement
also
provid
evid
may
use
biomark
clinic
develop
ifnb
random
placebocontrol
trial
ifnb
administ
peopl
asthma
histori
coldinduc
exacerb
therefor
conduct
test
hypothesi
deliv
oral
inhal
report
urti
ifnb
prevent
substanti
reduc
increas
asthma
symptom
therebi
provid
initi
proof
concept
ifnb
potenti
treatment
virusinduc
exacerb
result
studi
previous
report
form
abstract
random
doubleblind
parallel
placebocontrol
trial
ifnb
figur
involv
patient
histori
urtiinduc
exacerb
test
whether
inhal
scientif
knowledg
subject
peopl
asthma
like
develop
lower
respiratori
tract
symptom
cold
ie
upper
respiratori
tract
infect
specif
antivir
treatment
prevent
upper
respiratori
tract
infectioninduc
asthma
exacerb
studi
add
field
although
trial
meet
primari
endpoint
exploratori
subanalysi
difficulttotreatsubgroup
suggest
inhal
ifnb
enhanc
innat
immun
may
impact
favor
coldinduc
asthma
exacerb
patient
popul
ifnb
prevent
attenu
worsen
asthma
symptom
defin
rise
sixitem
junip
asthma
control
questionnair
caus
respiratori
virus
administ
within
hour
report
cold
influenza
symptom
primari
endpoint
defin
comparison
mean
chang
baselin
day
modifi
intentiontotreat
mitt
popul
ie
patient
fulfil
jackson
predi
criteria
cold
patient
respond
daili
text
messag
question
urti
symptom
met
preset
criteria
urti
attend
research
unit
within
hour
day
begin
treatment
inhal
ifnb
placebo
random
ratio
given
singl
daili
dose
day
patient
review
day
record
daili
upper
lower
respiratori
symptom
peak
expiratori
flow
pef
measur
home
see
tabl
full
studi
schedul
consist
recombin
formul
aqueou
solut
unlik
commerci
prepar
contain
mannitol
human
serum
albumin
ph
neutral
patient
receiv
miu
ifnb
placebo
formul
buffer
without
ifnb
portabl
mesh
nebul
deliv
minut
ineb
philip
respiron
chichest
uk
inclus
criteria
pretreat
phase
includ
age
year
asthma
symptom
greater
equal
year
confirm
histori
one
either
fev
revers
albuterol
ml
bronchial
hyperrespons
screen
histor
emerg
admiss
attend
primari
care
outofhour
clinic
worsen
asthma
histori
coldinduc
exacerb
greater
equal
one
exacerb
suspect
caus
respiratori
viru
past
month
requir
oral
corticosteroid
andor
antibiot
treatment
regular
inhal
corticosteroid
ic
ie
british
thorac
societi
bt
guidelin
step
patient
enter
treatment
phase
fulfil
follow
criteria
urti
symptom
within
last
hour
present
cold
symptom
block
runni
nose
sore
scratchi
throat
influenzalik
ill
temperatur
c
plu
two
either
headach
cough
sore
throat
myalgia
patient
belief
cold
flu
continu
regular
ic
sinc
screen
postbronchodil
fev
greater
equal
predict
patient
screen
histori
physic
examin
lung
function
test
bronchial
hyperrespons
asthma
diagnosi
requir
confirm
establish
asthma
control
screen
baselin
patient
complet
day
record
twice
daili
pef
respond
asthma
symptom
question
asthma
index
questionnair
twice
daili
jackson
cold
score
questionnair
jcsq
even
text
messag
establish
screen
baselin
patient
respond
daili
text
messag
ask
symptom
urti
see
onlin
supplement
respons
suggest
patient
experienc
cold
influenza
symptom
patient
telephon
assess
elig
treatment
phase
use
jcsq
confirm
onset
cold
symptom
within
past
hour
next
day
begin
treatment
day
text
messag
switch
question
jcsq
four
question
asthma
index
questionnair
symptom
chest
tight
wheez
cough
short
breath
score
complet
telephon
interview
day
treatment
baselin
treatment
day
nasal
lavag
collect
first
week
screen
panel
respiratori
virus
quantit
realtim
polymeras
chain
reaction
qpcr
sputum
induct
attempt
select
site
screen
treatment
day
quantifi
rv
viru
load
antivir
biomark
qpcr
proinflammatori
biomark
luminex
life
technolog
paisley
uk
blood
sampl
collect
measur
serum
elisa
genomewid
gene
express
analysi
primari
analysi
conduct
data
patient
fulfil
jackson
predi
criteria
figur
studi
design
pretreat
phase
patient
respond
daili
text
messag
inquir
symptom
cold
prespecifi
threshold
symptom
reach
visit
research
unit
within
hour
receiv
first
dose
thereaft
patient
receiv
daili
treatment
ifnb
placebo
total
day
primari
outcom
valid
shorten
version
asthma
control
questionnair
complet
screen
treatment
began
day
day
later
detail
biolog
sampl
collect
see
method
section
tabl
cold
patient
constitut
mitt
popul
statist
test
twosid
level
signific
adjust
multipl
primari
hypothesi
ifnb
superior
placebo
respect
chang
treatment
baselin
day
day
mitt
popul
test
analysi
covari
includ
term
pool
site
baselin
valu
sampl
size
calcul
base
data
prospect
multicent
studi
asthma
control
associ
cold
determin
patient
per
treatmentarm
provid
power
detect
mean
treatment
differ
chang
baselin
day
onset
cold
chang
accept
clinic
relev
betweenpati
standard
deviat
plan
mask
sampl
size
recalcul
perform
midstudi
result
requir
modif
addit
secondari
trial
endpoint
provid
onlin
supplement
statist
analysi
plan
also
state
exploratori
analys
patient
subgroup
defin
asthma
sever
may
investig
although
definit
sever
prespecifi
total
recruit
patient
consid
investig
develop
cold
random
treatment
phase
itt
popul
subsequ
analysi
show
patient
went
develop
cold
judg
fulfil
either
jackson
predi
cold
criteria
therefor
treat
mitt
popul
tabl
respiratori
virus
detect
qpcr
nasal
lavag
patient
one
viru
detect
sampl
virus
detect
rv
rest
adenoviru
bocaviru
coronaviru
enteroviru
human
metapneumoviru
parainfluenza
viru
respiratori
syncyti
viru
analysi
timecours
conduct
placebo
group
avoid
activ
treatment
effect
show
asthma
cold
symptom
increas
markedli
screen
baselin
peak
day
treatment
phase
gradual
return
baselin
figur
similar
trend
ifnb
group
figur
patient
complet
set
asthma
symptom
score
avail
day
ie
day
start
treatment
present
urti
cold
asthma
symptom
posit
correl
r
p
figur
miss
data
subject
exclud
analysi
primari
outcom
analysi
effect
treatment
treatment
baselin
day
day
primari
outcom
show
ifnb
superior
placebo
mitt
popul
figur
howev
ifnb
superior
placebo
assess
morn
pef
mean
definit
abbrevi
acq
asthma
control
questionnair
bt
british
thorac
societi
mitt
modifi
intentiontotreat
patient
fulfil
either
jackson
predi
criteria
cold
includ
mitt
group
clinic
import
differ
patient
random
receiv
ifnb
placebo
respect
clinic
criterion
either
assess
mitt
popul
whole
subgroup
asthma
sever
use
bt
step
atopi
percentag
may
alway
add
round
two
patient
take
mgday
inhal
corticosteroid
fluticason
equival
take
four
class
asthma
drug
part
normal
asthma
medic
therefor
assign
bt
step
subgroup
one
subject
take
mgday
inhal
corticosteroid
fluticason
equival
take
oral
corticosteroid
part
normal
asthma
medic
assign
bt
step
subgroup
group
differ
lmin
confid
interv
ci
p
area
curv
steadi
improv
ifnb
treatment
initi
declin
first
week
placebo
treatment
figur
also
trend
toward
reduc
sputum
rv
load
activ
group
day
mean
betweengroup
differ
log
copiesg
ci
p
figur
assess
blood
sputum
biomark
use
combin
immunoassay
qpcr
show
chang
consist
enhanc
antivir
activ
associ
attenu
proinflammatori
respons
patient
ifnb
treatment
treatment
serum
level
antivir
cytokin
increas
activ
placebotr
group
rel
screen
remain
elev
sever
day
ifnb
treatment
figur
wherea
fell
rapidli
placebo
differ
signific
day
p
respect
analyz
log
scale
via
analysi
covari
includ
day
covari
signific
reduct
proinflammatori
biomark
concentr
p
fluid
phase
sputum
patient
receiv
ifnb
treatment
day
figur
trend
toward
reduc
concentr
p
figur
without
betweengroup
differ
biomark
day
analysi
sputum
cell
pellet
qpcr
show
significantli
increas
gene
express
antivir
biomark
figur
figur
figur
day
p
respect
consequ
treatment
trend
toward
increas
day
p
respect
fewer
patient
receiv
ifnb
requir
addit
treatment
ie
oral
corticosteroid
antibiot
worsen
asthma
symptom
treatment
period
includ
one
subject
placebo
fail
meet
mitt
jcsq
criteria
data
miss
day
five
patient
receiv
placebo
requir
addit
treatment
four
requir
oral
corticosteroid
one
requir
antibiot
one
hospit
wherea
one
patient
ifnb
requir
oral
corticosteroid
import
placebotr
patient
requir
addit
treatment
difficulttotreat
patient
popul
categor
step
accord
bt
sever
criteria
keep
patient
sever
exacerb
viral
infect
analysi
placebotr
patient
classifi
use
bt
criteria
show
difficulttotreat
peopl
asthma
step
ie
step
develop
clinic
signific
increas
asthma
symptom
rise
cold
figur
support
observ
group
like
requir
addit
corticosteroid
antibiot
treatment
analysi
treatment
effect
primari
outcom
group
patient
show
mean
increas
placebo
group
n
decreas
ifnb
group
n
betweengroup
differ
p
figur
tabl
correspondingli
percentag
patient
individu
chang
greater
equal
significantli
lower
ifnb
compar
placebo
p
similarli
analysi
pef
chang
treatment
period
show
signific
ifnbrel
effect
step
patient
mean
betweengroup
differ
lmin
ci
p
area
curv
figur
tabl
step
subgroup
activ
placebo
treatment
statist
differ
respect
either
pef
although
mean
rise
step
subgroup
receiv
ifnb
greater
correspond
observ
chang
pef
favor
ifnb
tabl
analysi
effect
ifnb
treatment
respons
whole
mitt
group
also
perform
bt
step
subgroup
show
treatmentrel
increas
serum
level
similar
signific
entir
mitt
popul
see
figur
blood
sampl
collect
patient
mitt
popul
provid
uniqu
opportun
assess
post
hoc
analysi
effect
treatment
genomewid
gene
express
goodqual
data
analysi
obtain
patient
step
mitt
group
day
respect
differenti
express
gene
list
ifnb
versu
placebo
treatment
gener
day
gene
gene
select
probe
signific
p
less
fold
chang
greater
follow
analysi
covari
includ
day
covari
analysi
data
use
ingenu
pathway
analysi
softwar
ingenu
system
wwwingenuitycom
mountain
view
ca
suggest
enhanc
type
ifn
signal
day
figur
correct
multipl
test
use
benjaminihochberg
procedur
ifn
signal
canon
pathway
significantli
associ
dataset
p
p
day
respect
upstream
regul
analysi
show
predict
activ
transcript
factor
associ
type
ifn
signal
eg
ifn
regulatori
factor
multipl
regress
analysi
undertaken
explor
whether
baselin
assess
seem
relat
subsequ
chang
score
reflect
asthma
symptom
previou
potenti
treatment
effect
number
exacerb
last
month
screen
lung
function
bt
step
use
longact
bagonist
baselin
cold
asthma
symptom
score
identifi
potenti
relat
chang
treatment
baselin
day
base
subsequ
stepwis
regress
model
daili
asthma
symptom
score
treatment
day
posit
slope
higher
score
greater
increas
interact
studi
treatment
bt
step
seem
influenc
chang
interestingli
daili
cold
asthma
symptom
score
wors
activecompar
placebotr
bt
step
patient
immedi
start
treatment
take
daili
asthma
symptom
score
start
treatment
day
account
estim
differ
chang
ifnb
placebo
reduc
bt
step
p
p
increas
favor
ifnb
bt
step
group
p
see
tabl
overal
inhal
ifnb
well
toler
patient
stop
treatment
littl
differ
placebo
ifnb
frequenc
treatmentemerg
advers
event
except
palpit
experienc
five
subject
ifnb
none
placebo
mild
consid
clinic
signific
cardiac
event
record
see
tabl
studi
first
demonstr
abil
biolog
improv
antivir
respons
patient
asthma
also
associ
benefici
clinic
effect
view
good
exampl
translat
observ
enhanc
innat
immun
respons
ex
vivo
studi
proof
concept
clinic
studi
studi
suggest
given
time
report
urti
inhal
ifnb
amelior
way
airway
patient
asthma
respond
viral
infect
although
trial
show
posit
effect
primari
outcom
treatment
ifnb
posit
effect
morn
lung
function
pef
parallel
enhanc
innat
immun
system
lung
assess
serum
concentr
induct
gene
antivir
biomark
induc
sputum
associ
reduc
proinflammatori
cytokin
sputum
trend
toward
reduc
sputum
rv
load
analysi
moder
sever
peopl
asthma
step
accord
bt
guidelin
suggest
benefici
clinic
effect
treatment
shown
mean
reduct
score
patient
treat
ifnb
p
compar
placebo
wide
view
clinic
signific
genomewid
gene
express
analysi
use
circul
blood
cell
subset
patient
also
show
treatment
nebul
ifnb
enhanc
system
innat
immun
lack
effect
primari
outcom
surpris
whole
mitt
popul
also
includ
mild
peopl
asthma
sustain
increas
greater
equal
cold
onset
placebo
treatment
suggest
overal
exacerb
clinic
signific
whole
popul
studi
furthermor
prespecifi
analysi
state
statist
analysi
plan
patient
subgroup
asthma
sever
classifi
bt
treatment
step
criteria
show
signific
protect
effect
ifnb
patient
bt
step
ie
patient
requir
intens
asthma
mainten
treatment
studi
therefor
suggest
ifnb
treatment
may
appropri
difficult
control
peopl
asthma
underli
diseas
process
like
sever
thu
requir
intens
treatment
risk
exacerb
health
impact
treatment
cost
greatest
asthma
exacerb
major
target
novel
therapeut
agent
includ
biolog
omalizumab
mepolizumab
although
effect
reduc
exacerb
drug
given
longterm
system
pharmacodynam
unsuit
acut
administr
icss
mainstay
asthma
treatment
also
reduc
rate
exacerb
doubl
dose
onset
exacerb
reduc
sever
rate
recoveri
exacerb
thu
nebul
ifnb
treatment
first
therapi
act
causal
viral
pathway
seem
abl
prevent
worsen
asthma
symptom
administ
shortli
patient
becom
awar
cold
develop
ifnb
select
clinic
develop
base
abund
evid
safeti
multipl
sclerosi
efficaci
preclin
vitro
asthma
studi
accordingli
measur
biomark
serum
antivir
biomark
sputum
cell
demonstr
inhal
ifnb
activ
local
antivir
defens
mechan
effect
dose
frequenc
select
trial
time
attenu
proinflammatori
mediat
judg
concentr
measur
airway
secret
sputum
addit
ifnb
treatment
result
modest
signific
induct
system
innat
immun
respons
judg
genomewid
gene
express
analysi
blood
cell
show
signific
differ
gene
involv
type
ifn
signal
togeth
sustain
mark
elev
protein
level
blood
suggest
treatment
ifnb
enhanc
innat
immun
turn
improv
clinic
outcom
cold
trend
toward
reduc
load
rv
sputum
observ
treatment
suggest
better
antivir
defens
may
result
faster
clearanc
rv
studi
includ
analysi
virus
requir
definit
proof
note
bt
step
patient
lowdos
ic
shortact
bagonist
receiv
ifnb
mean
increas
howev
significantli
differ
placebo
analysi
pef
data
subgroup
support
deleteri
effect
ifnb
mirror
lack
ifnb
defici
observ
vitro
mild
patient
although
treatment
posit
effect
pef
patient
bt
step
although
number
patient
bt
step
group
rel
small
placebo
activ
exclud
possibl
ifnb
treatment
could
increas
asthma
symptom
small
number
patient
summari
studi
suggest
first
time
administr
ifnb
inhal
enhanc
innat
immun
local
within
lung
lesser
extent
system
therebi
compens
ifnb
defici
previous
demonstr
ex
vivo
epithelium
patient
moderatesever
asthma
possibl
benefici
clinic
effect
treatment
seen
patient
moderatesever
asthma
associ
enhanc
suggest
treatment
may
impact
favor
coldinduc
asthma
exacerb
trial
design
power
basi
entir
mitt
patient
popul
therefor
adequ
power
studi
focus
difficulttotreat
peopl
asthma
need
test
hypothesi
ifnb
effect
highrisk
patient
popul
n
